BioSpace News Archive

Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy.

Bot Image, Inc. introduced its Prostate Cancer detection, diagnosis, and screening software to the Urologist community at the recent AUA meeting in San Antonio, Texas and received rave reviews.

Ionis Pharmaceuticals, Inc. today announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome.

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential.

AIM ImmunoTech Inc. today reported its financial results for the first quarter 2024.

CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership team.

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 1/2 ALSpire study.

Soligenix, Inc. announced today that the results of its compatibility study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in the Journal of the European Academy of Dermatology & Venereology (JEADV) Clinical Practice.

Agenus Inc. today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL).

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD).